Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.05.015 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Alexis Talbot und 20 weiteren Autor:innen. Beteiligte Einrichtung: Hôpital Saint Louis, AP-HP, Paris, France. Electronic address: alexis.talbot@aphp.fr. Hauptthemen laut MEDLINE: Multiple Myeloma, ADP-ribosyl Cyclase 1, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Anti-CD38 monoclonal antibodies (aCD38) are increasingly used in early lines of therapies in multiple myeloma (MM). Retreatment with aCD38-based regimen is a widely used practice in later lines. However, data coming from clinical trials are currently limited. EMMY is a noninterventional, prospective dynamic cohort study conducted in 73 centers in France to assess the real-life management of MM in France and which can explore the efficacy of aCD38-based retreatment. METHODS: Patients who initiated a second line of treatment with aCD38-based combinations after a first exposure to aCD38 were identified and described and the outcomes of progression-free survival (PFS) and overall survival (OS) were estimated. RESULTS: In the EMMY cohort, 286 patients received 2 lines of treatment including aCD38. For all aCD38-retreated patients, median PFS was estimated at 5.1 months. Median PFS was 23.6 m in patients sensitive to aCD38 and 4.6 in nonsensitive patients, P = .0003. Median OS was estimated at 17.3 months for all patients,14.8 months in patients nonsensitive to aCD38, and not reached (NR) in sensitive patients, P = .0004. No significant differences in PFS or OS were observed between the refractory and nonrefractory to aCD38 groups. CONCLUSION: These results of aCD38 retreatment in a large sample of real-life patients (n = 286) in extensively pretreated patients show that retreatment may be a meaningful strategy for aCD38 sensitive patients. These findings need to be investigated further while the use of aCD38 is emerging as a first-line treatment for newly diagnosed patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hôpital Saint Louis, AP-HP, Paris, France. Electronic address: alexis.talbot@aphp.fr.
- CHU Pessac, Pessac, France.
- IUCT Oncopole, UMR 1037 Institut Universitaire du Cancer de Toulouse, France.
- CHU Caen, Caen, France.
- AP-HP, Hôpital Henri Mondor, Créteil, France.
- AP-HP, Hôpital Saint Antoine, Paris, France.
Zitieren
APA
Talbot, A., Hulin, C., Perrot, A., Macro, M., Belhadj Merzoug, K., Mohty, M., Bobin, A., Karlin, L., Manier, S., Vincent, L., Yamani, A. E., Abarah, W., Kaphan, R., Chalopin, T., Ré, D., de Labarthe, A., Fitoussi, O., Lounis, C., Garlantezec, R., …, & EMMY and the IFM group (2025). Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.05.015
Vancouver
Talbot A, Hulin C, Perrot A, Macro M, Belhadj Merzoug K, Mohty M, et al. Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.05.015
BibTeX
@article{Talbot2025,
author = {Talbot, Alexis and Hulin, Cyrille and Perrot, Aurore and Macro, Margaret and Belhadj Merzoug, Karim and Mohty, Mohamed and Bobin, Arthur and Karlin, Lionel and Manier, Salomon and Vincent, Laure and Yamani, Abderrazak El and Abarah, Wajed and Kaphan, Regis and Chalopin, Thomas and Ré, Daniel and de Labarthe, Adrienne and Fitoussi, Olivier and Lounis, Chanaz and Garlantezec, Ronan and Decaux, Olivier and EMMY and the IFM group, EMMY and the IFM group},
title = {Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.05.015}
}
EUVIMED